Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 first-in-human study of GSK5458514 in metastatic castration-resistant prostate cancer
jRCT2031250111Phase 2Recruiting
- Sponsor
- GSK
- Start
- Jun 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of GSK5458514 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by GSK. Primary endpoints: Incidence of dose-limiting toxicities (DLTs) and Incidence and severity of adverse events. Started Jun 2025; status: recruiting.
02
Drugs
GSK5458514
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2031250111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250111.